Skip to main content

Table 3 Correlations between peripheral lymphocyte subsets and clinicopathological features in ovarian

From: Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features

Variables Histology FIGO stage Platinum Response
HGSC CCC P Early (I + II) Late (III + IV) P Sensitive Resistant P
CD3+ T cells (%) 66.88 ± 9.46 73.27 ± 8.07 0.053 66.56 ± 10.91 67.27 ± 9.21 0.763 66.99 ± 7.44 66.07 ± 15.14 0.835
CD3+CD4+T cells (%) 38.43 ± 9.22 42.18 ± 7.65 0.241 39.19 ± 8.64 38.47 ± 9.18 0.748 39.48 ± 7.84 36.67 ± 12.59 0.458
CD3+CD8+ T cells (%) 26.49 ± 8.90 28.82 ± 10.94 0.464 26.73 ± 11.27 26.87 ± 8.93 0.951 27.63 ± 8.61 29.39 ± 12.85 0.565
CD8+CD28+ T cells (%) 7.07 ± 2.80 8.51 ± 2.88 0.145 7.70 ± 2.52 7.23 ± 2.83 0.489 7.53 ± 2.90 6.67 ± 3.58 0.374
NK cells (CD3CD56+) (%) 18.37 ± 8.95 14.30 ± 6.96 0.188 17.89 ± 10.08 18.15 ± 8.88 0.908 17.15 ± 7.34 21.64 ± 15.33 0.323
Tregs (CD4+CD25+CD127)(%) 12.91 ± 3.22 13.79 ± 4.14 0.445 13.20 ± 3.07 13.02 ± 3.26 0.830 12.50 ± 2.63 12.47 ± 4.24 0.976
B cells (CD19+) (%) 12.40 ± 5.24 10.20 ± 2.15 0.024 14.99 ± 5.81 12.13 ± 5.05 0.028 13.61 ± 6.03 9.86 ± 4.07 0.014
CD4/CD8 ratio 1.67 ± 0.85 1.74 ± 0.91 0.818 2.40 ± 2.69 1.64 ± 0.82 0.253 1.88 ± 1.83 1.55 ± 1.00 0.386
  1. Abbreviations: HGSC High-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, FIGO The International Federation of Gynecology and Obstetrics